Ariad Pharmaceuticals Company Profile (NASDAQ:ARIA)

About Ariad Pharmaceuticals

Ariad Pharmaceuticals logoARIAD Pharmaceuticals, Inc. (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company's product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company's Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). Its AP32788 is a TKI, which is designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in two kinases, epidermal growth factor receptor (EGFR), or human epidermal growth factor receptor 2 (HER2). Its Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: ARIA
  • CUSIP: 04033A10
Key Metrics:
  • Previous Close: $23.70
  • 50 Day Moving Average: $15.42
  • 200 Day Moving Average: $11.86
  • 52-Week Range: $4.37 - $23.81
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -67.86
  • P/E Growth: 23.20
  • Market Cap: $4.61B
  • Outstanding Shares: 194,200,000
  • Beta: 2.09
  • Net Margins: -16.99%
  • Return on Assets: -5.12%
  • Debt-to-Equity Ratio: -11.28%
  • Current Ratio: 3.17%
  • Quick Ratio: 3.15%
Additional Links:
Companies Related to Ariad Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Ariad Pharmaceuticals (NASDAQ:ARIA) (?)
Ratings Breakdown: 1 Sell Rating, 7 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.10)
Consensus Price Target: $15.39 (35.21% downside)

Analysts' Ratings History for Ariad Pharmaceuticals (NASDAQ:ARIA)
DateFirmActionRatingPrice TargetDetails
1/11/2017SunTrust Banks Inc.DowngradeBuy -> Hold$24.00View Rating Details
1/10/2017Cowen and CompanyReiterated RatingBuy$16.00View Rating Details
1/10/2017Leerink SwannDowngradeOutperform -> Market PerformView Rating Details
1/10/2017Barclays PLCUpgradeUnderweight -> Equal Weight$9.00 -> $24.00View Rating Details
1/10/2017Jefferies GroupDowngradeBuy -> Hold$11.00 -> $24.00View Rating Details
12/10/2016William BlairReiterated RatingOutperform$15.00View Rating Details
12/1/2016JMP SecuritiesReiterated RatingMarket PerformView Rating Details
11/3/2016Deutsche Bank AGInitiated CoverageHold$9.50View Rating Details
10/24/2016JPMorgan Chase & Co.DowngradeNeutral -> Underweight$9.97 -> $7.00View Rating Details
6/20/2016Royal Bank Of CanadaReiterated RatingHoldView Rating Details
2/22/2016Goldman Sachs Group Inc.Lower Price Target$7.00 -> $5.00View Rating Details
6/5/2015HC WainwrightReiterated RatingBuyView Rating Details
5/16/2015BMO Capital MarketsReiterated RatingOutperform$14.00View Rating Details
5/16/2015Stifel NicolausReiterated RatingBuyView Rating Details
(Data available from 1/21/2015 forward)


Earnings History for Ariad Pharmaceuticals (NASDAQ:ARIA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2016Q316($0.19)($0.12)$42.93 million$34.30 millionViewListenView Earnings Details
7/28/2016Q216($0.11)$0.59$60.64 million$65.30 millionViewListenView Earnings Details
5/10/2016Q116($0.27)($0.23)$43.06 million$35.60 millionViewListenView Earnings Details
2/23/2016Q415($0.32)($0.32)$44.79 million$36.50 millionViewListenView Earnings Details
11/3/2015Q315($0.23)($0.29)$46.09 million$27.50 millionViewListenView Earnings Details
8/5/2015Q215($0.27)($0.33)$33.24 million$27.80 millionViewListenView Earnings Details
5/7/2015Q115($0.27)($0.28)$27.26 million$23.90 millionViewListenView Earnings Details
2/19/2015Q414($0.20)($0.03)$39.50 million$66.00 millionViewListenView Earnings Details
11/5/2014Q314$0.30($0.27)$16.50 million$14.70 millionViewListenView Earnings Details
8/6/2014Q214($0.29)($0.30)$13.65 million$12.10 millionViewListenView Earnings Details
5/7/2014Q114($0.32)($0.27)$10.41 million$11.80 millionViewListenView Earnings Details
2/25/2014Q413($0.47)($0.40)$6.31 million$8.28 millionViewListenView Earnings Details
11/6/2013Q313($0.43)($0.36)$16.67 million$16.70 millionViewListenView Earnings Details
8/7/2013Q2 2013($0.40)($0.37)$11.11 million$13.90 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.38)($0.36)$5.01 million$6.40 millionViewListenView Earnings Details
2/25/2013Q4 2012($0.36)($0.36)$78.00 million$0.07 millionViewListenView Earnings Details
11/7/2012Q312($0.32)($0.32)$0.96 million$0.85 millionViewN/AView Earnings Details
8/2/2012($0.27)($0.31)ViewN/AView Earnings Details
5/9/2012($0.23)($0.35)ViewN/AView Earnings Details
2/28/2012($0.20)($0.38)ViewN/AView Earnings Details
11/3/2011$0.02$0.10ViewN/AView Earnings Details
8/2/2011($0.16)($0.36)ViewN/AView Earnings Details
5/5/2011($0.13)($0.29)ViewN/AView Earnings Details
2/17/2011($0.14)($0.25)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Ariad Pharmaceuticals (NASDAQ:ARIA)
Current Year EPS Consensus Estimate: $-0.03 EPS
Next Year EPS Consensus Estimate: $-0.35 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.34)($0.17)($0.27)
Q2 20162($0.11)($0.09)($0.10)
Q3 20164($0.21)($0.17)($0.19)
Q4 20164($0.19)($0.16)($0.18)
Q1 20172($0.24)($0.21)($0.23)
Q2 20172($0.23)($0.21)($0.22)
Q3 20172($0.22)($0.22)($0.22)
Q4 20172($0.57)($0.21)($0.39)
(Data provided by Zacks Investment Research)


Dividend History for Ariad Pharmaceuticals (NASDAQ:ARIA)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Ariad Pharmaceuticals (NASDAQ:ARIA)
Insider Ownership Percentage: 8.20%
Institutional Ownership Percentage: 85.16%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/9/2017Daniel M BollagVPSell32,000$23.78$760,960.00View SEC Filing  
10/24/2016Timothy P ClacksonInsiderSell19,638$9.56$187,739.28View SEC Filing  
10/3/2016Daniel M BollagVPSell47,384$13.46$637,788.64View SEC Filing  
9/28/2016Timothy P ClacksonInsiderSell8,750$13.98$122,325.00View SEC Filing  
9/22/2016Timothy P ClacksonInsiderSell20,000$13.43$268,600.00View SEC Filing  
9/15/2016Timothy P ClacksonInsiderSell59,369$11.73$696,398.37View SEC Filing  
8/22/2016Timothy P ClacksonInsiderSell19,436$10.47$203,494.92View SEC Filing  
8/12/2016Timothy P ClacksonInsiderSell25,000$10.50$262,500.00View SEC Filing  
7/22/2016Timothy P ClacksonInsiderSell18,286$8.11$148,299.46View SEC Filing  
6/28/2016Hugh M ColeSVPSell6,012$7.05$42,384.60View SEC Filing  
6/22/2016Timothy P ClacksonInsiderSell23,999$7.28$174,712.72View SEC Filing  
6/15/2016Athanese LavidasDirectorSell76,250$8.21$626,012.50View SEC Filing  
6/14/2016Massimo RadaelliDirectorSell108,569$8.25$895,694.25View SEC Filing  
5/23/2016Timothy P ClacksonInsiderSell17,762$8.08$143,516.96View SEC Filing  
5/12/2016Paris PanayiotopoulosCEOBuy26,990$7.41$199,995.90View SEC Filing  
5/2/2016Timothy P ClacksonInsiderSell11,700$7.13$83,421.00View SEC Filing  
4/22/2016Timothy P ClacksonInsiderSell21,409$7.37$157,784.33View SEC Filing  
3/22/2016Timothy P ClacksonInsiderSell23,834$6.58$156,827.72View SEC Filing  
3/21/2016David L BersteinSVPSell2,375$6.47$15,366.25View SEC Filing  
3/21/2016Edward M FitzgeraldVPSell5,417$6.47$35,047.99View SEC Filing  
3/21/2016Frank HaluskaCMOSell3,575$6.47$23,130.25View SEC Filing  
3/19/2016Maria E CantorSVPSell3,575$6.46$23,094.50View SEC Filing  
3/19/2016Martin J DuvallEVPSell4,000$6.47$25,880.00View SEC Filing  
3/19/2016Timothy P ClacksonInsiderSell5,417$6.47$35,047.99View SEC Filing  
3/3/2016Daniel M BollagVPSell9,625$6.11$58,808.75View SEC Filing  
3/3/2016Frank HaluskaCMOSell10,588$6.11$64,692.68View SEC Filing  
3/3/2016Timothy P ClacksonInsiderSell34,672$6.03$209,072.16View SEC Filing  
2/1/2016Edward M. FitzgeraldCFOSell14,667$4.81$70,548.27View SEC Filing  
2/1/2016Maria E. CantorSVPSell16,133$4.82$77,761.06View SEC Filing  
2/1/2016Paris PanayiotopoulosCEOBuy61,099$4.91$299,996.09View SEC Filing  
9/28/2015David L. BersteinSVPSell5,000$6.46$32,300.00View SEC Filing  
9/28/2015Frank HaluskaCMOSell5,500$6.46$35,530.00View SEC Filing  
9/28/2015Timothy P. ClacksoninsiderSell8,750$6.46$56,525.00View SEC Filing  
9/1/2015Maria E CantorSVPSell2,696$9.11$24,560.56View SEC Filing  
8/28/2015Edward M FitzgeraldCFOSell32,858$10.00$328,580.00View SEC Filing  
8/28/2015Maria E CantorSVPSell1,268$10.00$12,680.00View SEC Filing  
7/16/2015David L BersteinSVPSell4,000$8.54$34,160.00View SEC Filing  
7/16/2015Edward M FitzgeraldCFOSell7,000$8.54$59,780.00View SEC Filing  
7/16/2015Frank HaluskaCMOSell4,400$8.54$37,576.00View SEC Filing  
7/16/2015Martin J DuvallEVPSell1,400$8.54$11,956.00View SEC Filing  
5/1/2015Edward M FitzgeraldCFOSell60,000$8.80$528,000.00View SEC Filing  
4/23/2015Timothy P ClacksonInsiderSell123,766$9.50$1,175,777.00View SEC Filing  
3/23/2015Daniel M BollagVPSell7,000$8.72$61,040.00View SEC Filing  
3/23/2015Edward M FitzgeraldCFOSell9,584$8.72$83,572.48View SEC Filing  
3/23/2015Frank HaluskaCMOSell6,875$8.71$59,881.25View SEC Filing  
3/23/2015Maria E CantorSVPSell16,954$8.86$150,212.44View SEC Filing  
3/23/2015Martin J DuvallEVPSell4,834$8.80$42,539.20View SEC Filing  
3/23/2015Timothy P ClacksonInsiderSell32,741$8.88$290,740.08View SEC Filing  
2/12/2015Harvey J M D BergerCEOBuy25,000$6.83$170,750.00View SEC Filing  
2/2/2015Frank HaluskaCMOSell16,134$6.33$102,128.22View SEC Filing  
1/23/2015Harvey J M D BergerCEOBuy25,000$6.17$154,250.00View SEC Filing  
1/14/2015Sarah J SchlesingerDirectorBuy2,600$6.61$17,186.00View SEC Filing  
12/18/2014Harvey J M D BergerCEOBuy25,000$6.35$158,750.00View SEC Filing  
12/17/2014Sarah J SchlesingerDirectorBuy2,600$6.09$15,834.00View SEC Filing  
11/24/2014Maria E CantorSVPSell1,749$7.00$12,243.00View SEC Filing  
11/20/2014Harvey J M D BergerCEOBuy25,000$6.15$153,750.00View SEC Filing  
11/12/2014Sarah J SchlesingerDirectorBuy2,600$6.26$16,276.00View SEC Filing  
9/10/2014Sarah J SchlesingerDirectorBuy5,200$5.73$29,796.00View SEC Filing  
8/15/2014Alexander J DennerDirectorBuy850,000$5.83$4,955,500.00View SEC Filing  
4/2/2014Daniel BollagVPSell2,400$8.22$19,728.00View SEC Filing  
4/2/2014Frank HaluskaCMOSell3,400$8.21$27,914.00View SEC Filing  
4/2/2014Maria CantorSVPSell4,250$8.21$34,892.50View SEC Filing  
4/2/2014Timothy ClacksonInsiderSell6,500$8.21$53,365.00View SEC Filing  
3/21/2014Daniel BollagVPSell2,400$7.89$18,936.00View SEC Filing  
3/21/2014David BersteinSVPSell1,600$7.89$12,624.00View SEC Filing  
3/21/2014Timothy ClacksonInsiderSell6,667$7.89$52,602.63View SEC Filing  
12/19/2013David BersteinVPSell4,500$5.14$23,130.00View SEC Filing  
12/19/2013Frank HaluskaCMOSell5,100$5.14$26,214.00View SEC Filing  
12/19/2013Maria CantorSVPSell6,375$5.14$32,767.50View SEC Filing  
12/19/2013Timothy ClacksonInsiderSell9,750$5.14$50,115.00View SEC Filing  
9/6/2013Timothy P ClacksonInsiderSell8,449$22.00$185,878.00View SEC Filing  
8/14/2013Harvey BergerCEOSell118,759$18.34$2,178,040.06View SEC Filing  
7/18/2013Frank HaluskaCMOSell6,400$19.79$126,656.00View SEC Filing  
7/18/2013Maria E CantorSVPSell8,000$19.79$158,320.00View SEC Filing  
7/18/2013Timothy P ClacksonInsiderSell14,000$19.79$277,060.00View SEC Filing  
7/17/2013Harvey J M D BergerCEOSell199,400$19.84$3,956,096.00View SEC Filing  
6/19/2013Harvey J M D BergerCEOSell11,200$18.00$201,600.00View SEC Filing  
5/15/2013Harvey J M D BergerCEOSell92,498$18.10$1,674,213.80View SEC Filing  
3/26/2013Edward M FitzgeraldCFOSell12,933$18.75$242,493.75View SEC Filing  
3/25/2013Daniel M BollagVPSell12,933$18.87$244,045.71View SEC Filing  
3/25/2013Frank HaluskaCMOSell5,333$18.88$100,687.04View SEC Filing  
3/25/2013Pierre F DodionSVPSell8,133$18.87$153,469.71View SEC Filing  
3/25/2013Timothy P ClacksonInsiderSell19,167$18.87$361,681.29View SEC Filing  
3/13/2013Harvey J M D BergerCEOSell105,400$22.05$2,324,070.00View SEC Filing  
12/21/2012Athanese LavidasDirectorSell10,500$20.31$213,255.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Ariad Pharmaceuticals (NASDAQ:ARIA)
News IconARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) Daily Sentiment Score At 0 - Stock Observer (NASDAQ:ARIA) - January 21 at 3:34 PM logoCan The Uptrend Continue for ARIAD Pharmaceuticals (ARIA)? (NASDAQ:ARIA) - January 20 at 9:38 PM logoAriad Put Off Potential Suitor Amid 'Aggressive' Takeda Bid: RBC (NASDAQ:ARIA) - January 20 at 9:38 PM
News IconStock Crosses Into Overbought Range: ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) - Wall Street Beacon (NASDAQ:ARIA) - January 20 at 4:38 PM logoAriad played hardball to boost Takeda buyout price, federal filings show (NASDAQ:ARIA) - January 20 at 4:38 PM
News IconRecent Stock Surge Places it In Overbought Territory: ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) - Wall Street Beacon (NASDAQ:ARIA) - January 19 at 4:43 PM
News IconTechnicals in Focus for ARIAD Pharmaceuticals, Inc. (ARIA) - The USA Commerce (NASDAQ:ARIA) - January 19 at 4:43 PM
News IconAriad Pharmaceuticals Inc. (NASDAQ:ARIA) has 1 year Price Target of $20.63 (NASDAQ:ARIA) - January 18 at 4:14 PM
News IconTheIFP Advisors Inc invests in Ariad Pharmaceuticals Inc. (ARIA) Shares (NASDAQ:ARIA) - January 18 at 4:14 PM
News IconARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) Insiders Move Reflect Future Prospects (NASDAQ:ARIA) - January 18 at 4:14 PM logoBecton, Dickinson Commercially Launches Precise WTA Kits (NASDAQ:ARIA) - January 18 at 4:13 PM logoJazz Begins Phase III Study for Label Expansion of Defitelio (NASDAQ:ARIA) - January 18 at 4:13 PM logoAriad Pharmaceuticals, Inc. Acquisition May Not Be in the Best Interests of ARIA Shareholders (NASDAQ:ARIA) - January 18 at 4:13 PM
News IconApple App Store prices rise in UK, India and Turkey (NASDAQ:ARIA) - January 18 at 2:22 AM
News IconRecent analysts Ratings: Ariad Pharmaceuticals Incorporated (NASDAQ:ARIA) (NASDAQ:ARIA) - January 17 at 9:20 PM
News IconThe Ariad Pharmaceuticals Inc. (ARIA) Receives Buy Rating from Leerink Swann (NASDAQ:ARIA) - January 17 at 9:20 PM
News IconARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) Bearish Target At $24 - Stock Observer (NASDAQ:ARIA) - January 16 at 8:40 PM
News IconWill The Needle Move For ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:ARIA) - January 16 at 8:40 PM logoARIAD: Acquisition by Takeda Bodes Well, Competition a Risk - Yahoo Finance (NASDAQ:ARIA) - January 15 at 3:35 PM
News IconARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) Daily Sentiment Score At 0.102 - Stock Observer (NASDAQ:ARIA) - January 14 at 3:37 PM logoARIAD SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of ARIAD Pharmaceuticals, Inc ... - PR Newswire (press release) (NASDAQ:ARIA) - January 14 at 3:37 PM logoARIAD SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of ARIAD Pharmaceuticals, Inc. (ARIA) Over the Proposed Sale of the Company to Takeda Pharmaceutical Company Limited (NASDAQ:ARIA) - January 13 at 9:09 PM logoEarnings Key to Next Week's Winners: Cramer's 'Mad Money' Recap (Friday 1/13/17) (NASDAQ:ARIA) - January 13 at 9:09 PM
News IconMass. biotechs won’t commit to drug price cap (NASDAQ:ARIA) - January 13 at 4:06 PM logoARIAD: Acquisition by Takeda Bodes Well, Competition a Risk (NASDAQ:ARIA) - January 13 at 4:06 PM logoArQule (ARQL) Catches Eye: Stock Moves 7.2% Higher (NASDAQ:ARIA) - January 13 at 4:06 PM
News IconTrader's Buzzer: Ariad Pharmaceuticals, Inc (NASDAQ:ARIA) (NASDAQ:ARIA) - January 13 at 1:39 AM logoSHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of ARIAD ... - Business Wire (press release) (NASDAQ:ARIA) - January 12 at 8:39 PM logoSHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of ARIAD Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information (NASDAQ:ARIA) - January 12 at 8:39 PM
News IconARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) Quarterly EPS Set At $-0.39 - Stock Observer (NASDAQ:ARIA) - January 12 at 3:39 PM
News IconRSI Points to Potential Overbought Range For ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) - Wall Street Beacon (NASDAQ:ARIA) - January 12 at 3:39 PM
News IconARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) EPS Analysis - The Newburgh Press (NASDAQ:ARIA) - January 12 at 3:39 PM
News IconTakeda to buy USA cancer drug maker ARIAD Pharmaceuticals (NASDAQ:ARIA) - January 11 at 8:54 PM
News IconAriad Pharmaceuticals (ARIA) is Downgraded by SunTrust to Hold (NASDAQ:ARIA) - January 11 at 8:54 PM
News IconTakeda to buy Ariad Pharma for $4.7 billion (NASDAQ:ARIA) - January 11 at 8:54 PM logoAnalyst Downgrades – ARIAD Pharmaceuticals (NASDAQ:ARIA) Stock Gets Downgraded By SunTrust Banks, Inc. from ... - Market Exclusive (NASDAQ:ARIA) - January 11 at 3:52 PM
News IconEV Check on Shares of ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) - Wall Street Beacon (NASDAQ:ARIA) - January 11 at 3:52 PM logoFormer Ariad CEO Berger says Takeda deal was 'merely a matter of time' (NASDAQ:ARIA) - January 11 at 3:52 PM logoAriad Pharm downgraded by SunTrust (NASDAQ:ARIA) - January 11 at 3:52 PM logoTakeda Pharmaceutical Company Limited -- Moody's reviews Takeda Pharmaceutical's ratings for downgrade (NASDAQ:ARIA) - January 11 at 1:44 AM logoTakeda Takes the Hard Road (NASDAQ:ARIA) - January 11 at 1:44 AM logo[$$] Japan's Takeda Looks to More Acquisitions to Fuel Global Growth (NASDAQ:ARIA) - January 11 at 1:44 AM
News IconTakeda to acquire Ariad Pharmaceuticals (NASDAQ:ARIA) - January 10 at 8:43 PM logoAriad Pharmaceuticals Inc. (ARIA) Leaped To A New High After Bought By Takeda (NASDAQ:ARIA) - January 10 at 8:43 PM
News IconAriad Pharmaceuticals Will Be Acquired For $5.2 Billion In Cash, 75% Premium (NASDAQ:ARIA) - January 10 at 8:43 PM logoTakeda to acquire ARIAD Pharmaceuticals (ARIA) - M&A Call Slides (NASDAQ:ARIA) - January 10 at 8:43 PM logoAriad Pharm upgraded by Barclays (NASDAQ:ARIA) - January 10 at 8:43 PM logoAriad Pharmaceuticals Cash Acquisition by Takeda Pharmaceuticals Could a Second Buyer Surface (NASDAQ:ARIA) - January 10 at 3:40 PM logoARIAD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material D (NASDAQ:ARIA) - January 10 at 3:40 PM logoDrug Deal Is Bet Price Pressures Have Eased (NASDAQ:ARIA) - January 10 at 9:38 AM


Ariad Pharmaceuticals (NASDAQ:ARIA) Chart for Saturday, January, 21, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Ariad Pharmaceuticals (NASDAQ:ARIA)

Earnings History Chart

Earnings by Quarter for Ariad Pharmaceuticals (NASDAQ:ARIA)

Dividend History Chart

Dividend Payments by Quarter for Ariad Pharmaceuticals (NASDAQ:ARIA)

Last Updated on 1/21/2017 by Staff